FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287922012> ?p ?o ?g. }

• W4287922012 abstract "The purpose of this study was to evaluate endocrine therapy and chemotherapy for first-line, maintenance, and second-line treatment of hormone receptor-positive HER-2-negative metastatic breast cancer (HR+HER-2-MBC) and the relationship between different treatment options and survival.The patients included in this study were all diagnosed with metastatic breast cancer (MBC) at Shandong Cancer Hospital from January 2013 to June 2017. Of the 951 patients with MBC, 307 patients with HR+HER-2-MBC were included in the analysis. The progression-free survival (PFS) and overall survival (OS) of the various treatment modes were evaluated using Kaplan-Meier analysis and the log-rank test. Because of the imbalance in data, we used the synthetic minority oversampling technique (SMOTE) algorithm to oversample the data to increase the balanced amount of data.This retrospective study included 307 patients with HR+HER-2-MBC; 246 patients (80.13%) and 61 patients (19.87%) were treated with first-line chemotherapy and first-line endocrine therapy, respectively. First-line endocrine therapy was better than first-line chemotherapy in terms of PFS and OS. After adjusting for known prognostic factors, patients receiving first-line chemotherapy had poorer PFS and OS outcomes than patients receiving first-line endocrine therapy. In terms of maintenance treatment, the endocrine therapy-endocrine therapy maintenance mode achieved the best prognosis, followed by the chemotherapy-endocrine therapy maintenance mode and chemotherapy-chemotherapy maintenance mode, and the no-maintenance mode has resulted in the worst prognosis. In terms of first-line/second-line treatment, the endocrine therapy/endocrine therapy mode achieved the best prognosis, while the chemotherapy/chemotherapy mode resulted in the worst prognosis. The chemotherapy/endocrine therapy mode achieved a better prognosis than the endocrine therapy/chemotherapy mode. There were no significant differences in the KI-67 index (<15%/15-30%/≥30%) among the patients receiving first-line treatment modes, maintenance treatment modes, and first-line/second-line treatment modes. There was no statistical evidence in this study to support that the KI-67 index affected survival. However, in the first-line/second-line model, after SMOTE, we could see that KI-67 ≥ 30% had a poor prognosis.Different treatment modes for HR+HER-2-MBC were analyzed. Endocrine therapy achieved better PFS and OS outcomes than chemotherapy. Endocrine therapy should be the first choice for first-line, maintenance, and second-line treatment of HR+HER-2-MBC." @default.
• W4287922012 created "2022-07-26" @default.
• W4287922012 creator A5014295844 @default.
• W4287922012 creator A5050107377 @default.
• W4287922012 creator A5057134338 @default.
• W4287922012 creator A5066422384 @default.
• W4287922012 creator A5072370779 @default.
• W4287922012 creator A5075218387 @default.
• W4287922012 creator A5085956995 @default.
• W4287922012 date "2022-07-26" @default.
• W4287922012 modified "2023-09-30" @default.
• W4287922012 title "Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study" @default.
• W4287922012 cites W1803295013 @default.
• W4287922012 cites W1966804628 @default.
• W4287922012 cites W1968993577 @default.
• W4287922012 cites W1979832413 @default.
• W4287922012 cites W2029866800 @default.
• W4287922012 cites W2044702943 @default.
• W4287922012 cites W2057737812 @default.
• W4287922012 cites W2074351294 @default.
• W4287922012 cites W2081202499 @default.
• W4287922012 cites W2096283457 @default.
• W4287922012 cites W2112657305 @default.
• W4287922012 cites W2131106781 @default.
• W4287922012 cites W2158118614 @default.
• W4287922012 cites W2162755162 @default.
• W4287922012 cites W2164621703 @default.
• W4287922012 cites W2204530481 @default.
• W4287922012 cites W2290950904 @default.
• W4287922012 cites W2328198526 @default.
• W4287922012 cites W2404884142 @default.
• W4287922012 cites W2537305086 @default.
• W4287922012 cites W2552099557 @default.
• W4287922012 cites W2560367415 @default.
• W4287922012 cites W2560635244 @default.
• W4287922012 cites W2570874981 @default.
• W4287922012 cites W2606926876 @default.
• W4287922012 cites W2620993107 @default.
• W4287922012 cites W2760986981 @default.
• W4287922012 cites W2763875663 @default.
• W4287922012 cites W2796824128 @default.
• W4287922012 cites W2800938829 @default.
• W4287922012 cites W2896846857 @default.
• W4287922012 cites W2913589615 @default.
• W4287922012 cites W2948574507 @default.
• W4287922012 cites W2967901922 @default.
• W4287922012 cites W2988364315 @default.
• W4287922012 cites W2995593755 @default.
• W4287922012 cites W3010197652 @default.
• W4287922012 cites W3014453916 @default.
• W4287922012 cites W3083145960 @default.
• W4287922012 cites W3120899641 @default.
• W4287922012 cites W3128646645 @default.
• W4287922012 cites W3165114271 @default.
• W4287922012 cites W3197162231 @default.
• W4287922012 cites W4211032970 @default.
• W4287922012 cites W4240150780 @default.
• W4287922012 doi "https://doi.org/10.3389/fonc.2022.873570" @default.
• W4287922012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35957911" @default.
• W4287922012 hasPublicationYear "2022" @default.
• W4287922012 type Work @default.
• W4287922012 citedByCount "2" @default.
• W4287922012 countsByYear W42879220122022 @default.
• W4287922012 countsByYear W42879220122023 @default.
• W4287922012 crossrefType "journal-article" @default.
• W4287922012 hasAuthorship W4287922012A5014295844 @default.
• W4287922012 hasAuthorship W4287922012A5050107377 @default.
• W4287922012 hasAuthorship W4287922012A5057134338 @default.
• W4287922012 hasAuthorship W4287922012A5066422384 @default.
• W4287922012 hasAuthorship W4287922012A5072370779 @default.
• W4287922012 hasAuthorship W4287922012A5075218387 @default.
• W4287922012 hasAuthorship W4287922012A5085956995 @default.
• W4287922012 hasBestOaLocation W42879220121 @default.
• W4287922012 hasConcept C121608353 @default.
• W4287922012 hasConcept C126322002 @default.
• W4287922012 hasConcept C143998085 @default.
• W4287922012 hasConcept C167135981 @default.
• W4287922012 hasConcept C2775930923 @default.
• W4287922012 hasConcept C2776694085 @default.
• W4287922012 hasConcept C46699223 @default.
• W4287922012 hasConcept C530470458 @default.
• W4287922012 hasConcept C71315377 @default.
• W4287922012 hasConcept C71924100 @default.
• W4287922012 hasConceptScore W4287922012C121608353 @default.
• W4287922012 hasConceptScore W4287922012C126322002 @default.
• W4287922012 hasConceptScore W4287922012C143998085 @default.
• W4287922012 hasConceptScore W4287922012C167135981 @default.
• W4287922012 hasConceptScore W4287922012C2775930923 @default.
• W4287922012 hasConceptScore W4287922012C2776694085 @default.
• W4287922012 hasConceptScore W4287922012C46699223 @default.
• W4287922012 hasConceptScore W4287922012C530470458 @default.
• W4287922012 hasConceptScore W4287922012C71315377 @default.
• W4287922012 hasConceptScore W4287922012C71924100 @default.
• W4287922012 hasLocation W42879220121 @default.
• W4287922012 hasLocation W42879220122 @default.
• W4287922012 hasLocation W42879220123 @default.
• W4287922012 hasOpenAccess W4287922012 @default.
• W4287922012 hasPrimaryLocation W42879220121 @default.
• W4287922012 hasRelatedWork W2139647583 @default.
• W4287922012 hasRelatedWork W2348231456 @default.

• next